Bayer completes recruitment of first cohort for BAY 86-6150 Stage II/III research in hemophilia Bayer's BAY 86-6150 has been investigated in a Stage II/III research called TRUST , and the recruitment of the initial cohort is currently complete. Recruitment is usually ongoing at sites located all over the world, including in the U www.levitra-danmark.net more info .S., where sites will be ready to enroll eligible individuals. ‘Bayer is focused on finding innovative methods to meet the requirements of individuals with hemophilia, including those suffering from the consequences of inhibitors to clotting aspect replacement therapies,’ stated Pamela Cyrus, MD, Vice Head and President, U.S.

Other articles from category "gastroenterology":

Random articles